Cervical villoglandular adenocarcinoma: a rare case report and review of the literature

Villoglandular adenocarcinoma (VGA) is a rare variant of cervical adenocarcinoma classified as HPV-associated. We encountered a case of cervical VGA with no evidence of HPV infection reported below. A 50-year-old woman accidentally discovered cervical polyps during gynecological physical examination. After removal, the pathological examination was diagnosed as cervical VGA, and immunohistochemistry showed that p16 was focal positive expression. We reviewed the relevant literature to summarize the clinicopathological features of VGA and the key points of pathological diagnosis and differential diagnosis.

Villoglandular adenocarcinoma; Adult; Female; Humans; Cervix; Pathology

[1] Young RH, Scully RE. Villoglandular papillary adenocarcinoma of the uterine cervix. A clinicopathologic analysis of 13 cases. Cancer. 1989; 63: 1773–1779.

[2] McCluggage WG, Singh N, Gilks CB. Key changes to the world health organization (WHO) classification of female genital tumours introduced in the 5th edition (2020) histopathology. 2022; 80: 762–778.

[3] Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, et al. International endocervical adenocarcinoma criteria and classification (IECC). American Journal of Surgical Pathology. 2018; 42: 214–226.

[4] Turashvili G, Park KJ. Cervical glandular neoplasia. Surgical Pathology Clinics. 2019; 12: 281–313.

[5] Heatley MK. Villoglandular adenocarcinoma of the uterine cervix? A systematic review of the literature. Histopathology. 2007; 51: 268–269.

[6] Korach J, Machtinger R, Perri T, Vicus D, Segal J, Fridman E, et al. Villoglandular papillary adenocarcinoma of the uterine cervix: a diagnostic challenge. Acta Obstetricia et Gynecologica Scandinavica. 2009; 88: 355–358.

[7] Zhang Y, Wang Y, Liu Y, Yang J, Liu C. A retrospective study and literature review of cervical villoglandular adenocarcinoma: a candidate paradigm of silva system pattern A. Applied Immunohistochemistry & Molecular Morphology. 2021; 29: 467–472.

[8] Alfsen GC, Reed W, Abeler VM. Reproducibility of classification in non-squamous cell carcinomas of the uterine cervix. Gynecologic Oncology. 2003; 90: 282–289.

[9] Zhao L, Xu T, Cui M, Fu Z. A retrospective review of 11 cases of villoglandular papillary adenocarcinoma of the uterine cervix and a review of the literature. Oncology Letters. 2016; 11: 2164–2168.

[10] Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology. 2002; 41: 185–207.

[11] Shen H, Huang Z, Zhang S, Zhang Y, An J, Luo J, et al. The clinicopathologic and immunohistochemical features of villoglandular adenocarcinoma of uterine cervix. Indian Journal of Pathology and Microbiology. 2018; 61: 549.

[12] Guo P, Liu P, Yang J, Ren T, Xiang Y. Villoglandular adenocarcinoma of cervix: Pathologic features, clinical management, and outcome. Cancer Management and Research. 2018; 10: 3955–3961.

[13] McCluggage WG. Progress in the pathological arena of gynecological cancers. International Journal of Gynecology & Obstetrics. 2021; 155: 107–114.

[14] Ren H, Almadani N, Pors J, Leung S, Ho J, Chow C, et al. International endocervical adenocarcinoma criteria and classification (IECC): an independent cohort with clinical and molecular findings. International Journal of Gynecological Pathology. 2021; 40: 533–540.

[15] Stolnicu S, Hoang L, Soslow RA. Recent advances in invasive adenocarcinoma of the cervix. Virchows Archiv. 2019; 475: 537–549.